Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lamivudine in Combination With Chemoimmunotherapy in Patients With Extensive Stage SCLC
NCT04696575Phase 2Recruiting
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Jul 2021
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lamivudine in small cell lung cancer (SCLC), sponsored by Roswell Park Comprehensive Cancer Center. Started Jul 2021; status: recruiting.
02
Drugs
lamivudine
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04696575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04696575.